Literature DB >> 1542332

Prophylactic fluconazole and Candida krusei infection.

R O Casasnovas, D Caillot, E Solary, B Bonotte, P Chavanet, A Bonin, P Camerlynck, H Guy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542332

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

3.  Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients.

Authors:  D Sullivan; D Bennett; M Henman; P Harwood; S Flint; F Mulcahy; D Shanley; D Coleman
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

4.  Differential and enrichment media for selective culture and recognition of yeast species from clinical material.

Authors:  B Louwagie; I Surmont; J Verhaegen; F Odds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

5.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 6.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.